AN2 Therapeutics Inc. (ANTX)
NASDAQ: ANTX
· Real-Time Price · USD
1.07
-0.03 (-2.73%)
At close: Jun 23, 2025, 3:59 PM
1.09
1.87%
After-hours: Jun 23, 2025, 07:12 PM EDT
-2.73% (1D)
| Bid | 1.05 |
| Market Cap | 32.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -45.35M |
| EPS (ttm) | -1.51 |
| PE Ratio (ttm) | -0.71 |
| Forward PE | -0.82 |
| Analyst | Buy |
| Ask | 1.15 |
| Volume | 55,917 |
| Avg. Volume (20D) | 215,372 |
| Open | 1.09 |
| Previous Close | 1.10 |
| Day's Range | 1.07 - 1.12 |
| 52-Week Range | 0.87 - 3.07 |
| Beta | -0.08 |
About ANTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ANTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ANTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+0%
AN2 Therapeutics shares are trading lower after th...
Unlock content with
Pro Subscription
10 months ago
-60.98%
AN2 Therapeutics shares are trading lower after the company announced that it will discontinue its EBO-301 study following topline results from its Phase 2 part of the study in treatment-refractory patients with MAC lung disease.
